Evommune, Inc. is a clinical-stage biotechnology company focused on therapies for chronic inflammatory diseases, including atopic dermatitis and chronic spontaneous urticaria. Despite ongoing operating losses, the company strengthened its balance sheet through a successful IPO in late 2025 and continued financing into early 2026, supporting ongoing R&D efforts. Key clinical milestones include positive Phase 2a data from EVO301 in atopic dermatitis, bolstering potential commercialization prospects. The company’s financial position as of year-end 2025 shows $44 million in cash and equivalents and a current ratio of approximately 8.6, supporting an operational runway into mid-2028. Risks remain related to regulatory approval, funding needs, and commercialization challenges.